product pipeline / R&D affecting expense
“Other research and development expenses increased by $1.2 million primarily due to an increase in consulting expenses to support our programs.”
CLYM 10-K
Confirmed
Biotechnology Therapeutics
32 names are moving together; 63% are participating in the current session.
3 observed Confirmed episodes
Co-movement
Observed member paths adjusted against SPY. Shading marks the latest observation window.
Members
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| ZVRA | Zevra Therapeutics, Inc. | Healthcare | -4.3% | 3/13 observed active sessions |
| ABSI | Absci Corporation | Healthcare | -7.6% | Group member |
| DNLI | Denali Therapeutics Inc. | Healthcare | -5.6% | 2/13 observed active sessions |
| ABEO | Abeona Therapeutics Inc. | Healthcare | -2.2% | 5/13 observed active sessions |
| GRAL | GRAIL, Inc. | Healthcare | -5.0% | 1/13 observed active sessions |
| CRSP | CRISPR Therapeutics AG | Healthcare | -5.3% | 3/13 observed active sessions |
| ZLAB | Zai Lab Limited | Healthcare | +2.7% | Group member |
| PLSE | Pulse Biosciences, Inc | Healthcare | -3.7% | 4/13 observed active sessions |
| BEAM | Beam Therapeutics Inc. | Healthcare | -8.7% | 2/13 observed active sessions |
| CCCC | C4 Therapeutics, Inc. | Healthcare | -5.2% | Group member |
| CABA | Cabaletta Bio, Inc. | Healthcare | -4.5% | Group member |
| PRTA | Prothena Corporation plc | Healthcare | -4.2% | 2/13 observed active sessions |
| CLYM | Climb Bio, Inc. | Healthcare | +1.4% | 4/13 observed active sessions |
| SLDB | Solid Biosciences Inc. | Healthcare | -6.5% | Group member |
| SLS | SELLAS Life Sciences Group, Inc | Healthcare | -5.7% | Group member |
| TNXP | Tonix Pharmaceuticals Holding C | Healthcare | -3.7% | 3/13 observed active sessions |
| CADL | Candel Therapeutics, Inc. | Healthcare | -4.2% | Group member |
| MLTX | MoonLake Immunotherapeutics | Healthcare | +2.1% | Group member |
| INBX | Inhibrx Biosciences, Inc. | Healthcare | -10.5% | 4/13 observed active sessions |
| GHRS | GH Research PLC | Healthcare | -1.9% | 1/13 observed active sessions |
| SGMT | Sagimet Biosciences Inc. - Seri | Healthcare | +0.6% | 3/13 observed active sessions |
| EDIT | Editas Medicine, Inc. | Healthcare | -0.8% | Group member |
| CLPT | ClearPoint Neuro Inc. | Healthcare | -2.1% | 2/13 observed active sessions |
| STAK | STAK Inc. | Energy | -10.7% | Group member |
Why we believe this
Cohort
32 namesParticipation
63% this sessionObserved history
18 daily buildsFiling coverage
30/32 membersrestructuring affecting expense
“Personnel-related expenses decreased by $0.9 million due primarily to prior year restructuring costs, partially offset by increased headcount.”
CLYM 10-Q
restructuring
“If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the delay, reduction, termination or restructuring of our operations.”
CLYM 10-Q
This identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
Connected, outside the group
PFE
ALLOsupplier · Not moving with the group now
Filing receipt · PFE / ALLO
“In April 2018, we acquired certain assets from Pfizer Inc.”
ALLO · supplier
MRK
CCCCpartner · Not moving with the group now
Filing receipt · MRK / CCCC
“Merck KGaA Collaboration and License Agreement In March 2024, we entered into a license and collaboration agreement with Merck KGaA, or the Merck KGaA Agreement, to disc…”
CCCC · partner
BIIB
DNLIpartner · Not moving with the group now
Filing receipt · BIIB / DNLI
“PGRN levels in the brain with the goal of treating frontotemporal dementia ("FTD") associated with a mutation in the granulin ("GRN") gene and is being developed in coll…”
DNLI · partner
LLY
CRSPcustomer · Not moving with the group now
Filing receipt · LLY / CRSP
“We have also established a collaboration and clinical supply agreement with Eli Lilly to evaluate zugo-cel together with pirtobrutinib in aggressive B-cell lymphomas, fu…”
CRSP · customer
BMY
PRTApartner · Not moving with the group now
Filing receipt · BMY / PRTA
“Our active clinical portfolio includes prasinezumab currently being evaluated in the Phase 3 PARAISO clinical trial for the treatment of early Parkinson’s disease in par…”
PRTA · partner
History
2026-07-07 → 2026-07-135 observed active sessions · 0% of active names held across the episode
2026-06-23 → 2026-07-027 observed active sessions · 0% of active names held across the episode
2026-06-171 observed active session · 100% of active names held across the episode